Combination Therapies for Multiple Myeloma

Chapter 4

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the complexity and potential of the many possible treatment combinations now available for patients with multiple myeloma.

Chapter 1

The Future Focus of LLS Research

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how she is directing the LLS’s research focus.

Chapter 2

MDM2: A Therapeutic Target?

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the potential of targeting MDM2 for hematologic cancers.

Chapter 3

p53 Dysregulation: Causes and Effects

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the role of p53 in oncogenesis and the proliferation of various cancers.

Chapter 5

The Future of Treating Hematologic Cancers

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how the treatment of hematologic cancers is likely to change, including the roles biomarkers and epigenetics are likely to play in personalized care.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs